Focus Investment Banking

JUNE 13, 2023

according to a recent report by researchers from the Harvard Medical School and the Harvard Business School that was published in JAMA Internal Medicine. Similarly, PE-backed platform companies have undergone substantial consolidation through mergers and acquisitions.” Tahoe still owns a minority interest. US Oncology Network.

Hospitality 52

Hospitality Private Equity Mergers and Acquisitions Medical 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

OfficeHours

JULY 18, 2023

One of these “new” strategies that has grown in popularity over the past decade is the concept of “roll-ups” (also sometimes called “platform acquisition strategies”). This begs an important question: why do roll-ups receive a higher value than smaller acquisition targets? and thus receive volume discounts with better pricing.

Private Equity 130

Private Equity Equities Investment Mergers and Acquisitions 130

Cooley M&A

JANUARY 25, 2023

The year started off with a bang, with mega-deals such as Microsoft’s pending $69 billion acquisition of Activision Blizzard, Elon Musk’s $44 billion acquisition of Twitter and Broadcom’s pending $61 billion acquisition of VMware inked in quick succession. Tech M&A in 2022 was a tale of two halves.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40